Cancer Institute A national cancer institute
designated cancer center

Stanford: A Center of Lymphoma Excellence

The Stanford Lymphoma Program is comprised of a dedicated core of individuals who have pioneered significant advances in the treatment of lymphoma. Members of this team are routinely recognized and awarded for their contributions to the field, including a profile in US News & World Report’s “America’s Best Hospitals,” 2011-12 issue.

Lymphoma Program patients, both adults and children, benefit from treatment by experienced professionals who participate in the clinical trial development of promising new lymphoma treatments often not yet available at other facilities. Examples include:

  • Targeted therapies that attack signaling pathways in tumor cells, including:
    • Brentuximab vedotin (SGN-35), an antibody-drug conjugate that targets CD30, the defining marker of Hodgkins Lymphoma
    • Oral inhibitor of Bruton tyrosine kinase (Btk), a crucial part of the signaling pathway required for B cell growth
    • Radioimmunotherapy, a specialized treatment whereby toxic molecules are delivered to cancer cells by radioactive antibodies
  • Development of patient customized vaccines to treat lymphoma by identifying and applying the unique signature of each lymphoma tumor
  • Unique and highly curative chemotherapy/radiotherapy regimens for Hodgkins lymphoma, aimed to preserve fertility and reduce long-term complications
  • Blood and marrow transplantation using allogeneic or autologous marrow grafting
  • New imaging techniques using radiologic tracers for better delineation of disease
  • Opportunities to participate in clinical trials conducted by national cooperative groups that lead the integration of new therapeutics and imaging


Stanford Medicine Resources:

Footer Links: